Skip to main content
Premium Trial:

Request an Annual Quote

OraSure Completes $50.6M Buy of DNA Genotek

NEW YORK (GenomeWeb News) – OraSure Technologies today announced it has completed its purchase of DNA Genotek for C$50 million (US$50.6 million) in cash.

DNA Genoteck, based in Ottawa, Ontario, will operate as a wholly owned subsidiary of OraSure. The deal, announced in late July, provides OraSure a complementary portfolio of products for the collection, stabilization, transportation, and storage of high quality nucleic acid samples, which can then be used for diagnostic and research purposes.

It also gives Bethlehem, Pa-based OraSure, whose products include antibody-based assays for infectious diseases, a presence in the molecular diagnostics space.

DNA Genoteck has more than 3,000 customers in more than 100 countries, OraSure said. In 2010, DNA Genotek generated approximately $14 million in revenues.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.